Nurix Therapeutics, Inc. (NASDAQ: NRIX) reported Q3 EPS of ($0.68), $0.16 better than the analyst estimate of ($0.84). Revenue for the quarter came in at $18.47 million versus the consensus estimate of $11.94 million.

For earnings history and earnings-related data on Nurix Therapeutics, Inc. (NRIX) click here.